Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two …

P Lombardi, D Rossini, V Crespi, MM Germani… - Cancer Treatment …, 2022 - Elsevier
… Ten studies included patients treated with bevacizumab in the first line setting, whereas four
… the correlation between bevacizumab-induced HTN and survival outcomes in patients with …

[HTML][HTML] Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

Á Rodríguez-Lescure, J Gallego… - … Translational Oncology, 2024 - Springer
Arterial hypertension (AHT) is a common toxicity with bevacizumab (BVZ)-containing …
Once we could not correlate the AHT, with PFS to CT/BVZ, we evaluated several cut-offs of …

… hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor …

H Osumi, E Shinozaki, A Ooki, T Wakatsuki… - Cancer …, 2021 - Wiley Online Library
bevacizumab (BEV) exposure in mCRC patients who were … In this study a strong correlation
was observed between the … especially in patients treated with BEV in first-line chemotherapy. …

[HTML][HTML] Clinical Outcome of Colorectal Cancer Patients with Concomitant Hypertension: A Systematic Review and Meta-Analysis

D Sur, CI Coroama, A Audisio, R Fazio… - Journal of Personalized …, 2024 - mdpi.com
… Background: Arterial hypertension is regarded as a possible … that HTN is positively correlated
with CRC risk and can bring … analysed only the impact of bevacizumab-related HTN, whilst …

[HTML][HTML] Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer

G Marisi, I Azzali, A Passardi, F Rebuzzi, G Bartolini… - Scientific Reports, 2023 - nature.com
… The primary objective of the study was to assess the correlation of the selected polymorphisms
with PFS. Secondary objectives were the correlations with OS and ORR. The Local Ethics …

[HTML][HTML] … VEGF-a and ACE plasma levels of metastatic colorectal cancer patients have prognostic value for first-line treatment with chemotherapy plus bevacizumab

MJ Ortiz-Morales, M Toledano-Fonseca… - Cancers, 2022 - mdpi.com
… -EGFR; no indication for bevacizumab due to uncontrolled arterial hypertension and/or …
correlation between plasma VEGF-A and outcomes in mCRC patients treated with bevacizumab

[HTML][HTML] Cardiovascular complications of metastatic colorectal cancer treatment

K Keramida, G Charalampopoulos… - … Oncology, 2019 - ncbi.nlm.nih.gov
… During first-line treatment, 90% of patients … ), pulmonary embolism (PE) and thrombophlebitis.
However, the added risk of bevacizumab to VTEs is ambiguous, since cancer patients are …

The Effect of Bevacizumab-Related Hypertension on the Prognosis of Patients with Colorectal Cancer and Non-Small Cell Lung Cancer.

J Pan, L Zheng, B Liu, S You… - Indian Journal of …, 2022 - search.ebscohost.com
… and it is often used as the first-line therapy for metastatic colorectal cancer and locally
advanced, recurrent or … Therefore, the correlation between bevacizumab and the prognosis of …

[HTML][HTML] … with outcome of metastatic colorectal cancer patients treated with bevacizumab-based therapy: a single-institution retrospective analysis of 514 patients

O Fiala, P Ostasov, O Sorejs, V Liska, T Buchler… - Cancers, 2019 - mdpi.com
arterial hypertension induced by bevacizumab is associated with a favourable outcome in
mCRC patients [68]… On the other hand, the inclusion of these patients might introduce immortal …

Bevacizumab in combination with TAS‐102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: A retrospective study

H Fujii, N Matsuhashi, M Kitahora, T Takahashi… - The …, 2020 - academic.oup.com
correlation between Bmab and OS. The incidence of … combined treatment with Bmab
improves clinical outcomes, we … safety of treatment with or without bevacizumab in patients with …